



ELSEVIER

Clinica Chimica Acta 291 (2000) 243–245



www.elsevier.com/locate/clinchim

Author index

Volume 291 (2000)

- Ahram, M., see Koblinksi, J.E. 291, 113
Allcock, K., see Delanghe, J. 291, 43
Ardissino, D., Merlini, P.A., Arlens, R., Coppola, R., Bramucci, E., Lucreziotti, S., Repetto, A., Fetiveau, R., Mannucci, P.M., Tissue factor in human coronary atherosclerotic plaques 291, 235
Arlens, R., see Ardissino, D. 291, 235

Balbín, M., see Pendás, A.M. 291, 137
Baron, R., see Delaissé, J.-M. 291, 223
Basso, L.E., Ubbink, J.B., Delpont, R., Erythrocyte magnesium concentration as an index of magnesium status: a perspective from a magnesium supplementation study 291, 1
Beer, C., see Masuda, M. 291, 53
Bramucci, E., see Ardissino, D. 291, 235
Brguljan, P.M., see Cimerman, N. 291, 89

Caccin, P., see Rossetto, O. 291, 189
Cardin, R., see Herszényi, L. 291, 171
Carraro, P., see Herszényi, L. 291, 171
Chen, S., see Masuda, M. 291, 53
Christiansen, M., Høgdall, C.K., Høgdall, E.V.S., Alpha-fetoprotein in human fetal cerebrospinal fluid 291, 35
Cimerman, N., Brguljan, P.M., Krašovec, M., Šuškovič, S., Kos, J., Twenty-four hour variations of cystatin C and total cysteine proteinase inhibitory activity in sera from healthy subjects 291, 89
Claeys, L., see Delanghe, J. 291, 43
Coppola, R., see Ardissino, D. 291, 235

de Bernard, M., see Rossetto, O. 291, 189
De Buyzere, M., see Delanghe, J. 291, 43

del Carmen Ovejero, M., see Delaissé, J.-M. 291, 223
Delaissé, J.-M., Engsig, M.T., Everts, V., del Carmen Ovejero, M., Ferreras, M., Lund, L., Vu, T.H., Werb, Z., Winding, B., Lochter, A., Karsdal, M.A., Troen, T., Kirkegaard, T., Lenhard, T., Heegaard, A.-M., Neff, L., Baron, R., Foged, N.T., Proteinases in bone resorption: obvious and less obvious roles 291, 223
Delanghe, J., Allcock, K., Langlois, M., Claeys, L., De Buyzere, M., Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography 291, 43
Delpont, R., see Basso, L.E. 291, 1
De Paoli, M., see Herszényi, L. 291, 171
Dionisi-Vici, C., see Rizzo, C. 291, 97
D'Ippoliti, M., see Rizzo, C. 291, 97


Engsig, M.T., see Delaissé, J.-M. 291, 223
Everts, V., see Delaissé, J.-M. 291, 223

Farinati, F., see Herszényi, L. 291, 171
Federici, G., see Rizzo, C. 291, 97
Fergelot, P., see Massart, C. 291, 67
Ferreras, M., see Delaissé, J.-M. 291, 223
Fetiveau, R., see Ardissino, D. 291, 235
Fichna, P., see Masuda, M. 291, 53
Fina, F., see Rizzo, C. 291, 97
Foged, N.T., see Delaissé, J.-M. 291, 223
Foschia, F., see Herszényi, L. 291, 171
Freije, J.P., see Pendás, A.M. 291, 137
Furmaniak, J., see Masuda, M. 291, 53

Garcia, M., see Rochefort, H. 291, 157
Gibassier, J., see Massart, C. 291, 67

- Glondou, M., see Rochefort, H. 291, 157
- Goldberg, D.M., Proteases in the evaluation of pancreatic function and pancreatic disease 291, 201
- Gotto Jr., A.M., see Lambert, D.A. 291, 19
- Harigae, H., see Kudo, S. 291, 83
- Heegaard, A.-M., see Delaissé, J.-M. 291, 223
- Herszényi, L., Plebani, M., Carraro, P., De Paoli, M., Roveroni, G., Cardin, R., Foschia, F., Tulasay, Z., Naccarato, R., Farinati, F., Proteases in gastrointestinal neoplastic diseases 291, 171
- Høgdaal, C.K., see Christiansen, M. 291, 35
- Høgdaal, E.V.S., see Christiansen, M. 291, 35
- Imaizumi, M., see Kudo, S. 291, 83
- Imamura, T., see Namera, A. 291, 9
- Jiménez, M.G., see Pendás, A.M. 291, 137
- Kaku, M., see Kudo, S. 291, 83
- Kameoka, J.-i., see Kudo, S. 291, 83
- Karsdal, M.A., see Delaissé, J.-M. 291, 223
- Kimura, J., see Kudo, S. 291, 83
- Kirkegaard, T., see Delaissé, J.-M. 291, 223
- Koblinski, J.E., Ahram, M., Sloane, B.F., Unraveling the role of proteases in cancer 291, 113
- Kojima, T., see Namera, A. 291, 9
- Kos, J., see Cimerman, N. 291, 89
- Krašovec, M., see Cimerman, N. 291, 89
- Kudo, S., Harigae, H., Watanabe, N., Takasawa, N., Kimura, J., Kameoka, J.-i., Meguro, K., Imaizumi, M., Kaku, M., Sasaki, T., Increased HbF levels in dyserythropoiesis 291, 83
- Lambert, D.A., Smith, L.C., Pownall, H., Sparrow, J.T., Nicolas, J.-P., Gotto Jr., A.M., Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments 291, 19
- Langlois, M., see Delanghe, J. 291, 43
- Laurent, V., see Rochefort, H. 291, 157
- Lenhard, T., see Delaissé, J.-M. 291, 223
- Liaudet, E., see Rochefort, H. 291, 157
- Lochter, A., see Delaissé, J.-M. 291, 223
- López-Otín, C., see Pendás, A.M. 291, 137
- Lucreziotti, S., see Ardissino, D. 291, 235
- Lund, L., see Delaissé, J.-M. 291, 223
- Mannucci, P.M., see Ardissino, D. 291, 235
- Massart, C., Gibassier, J., Vêrité, F., Fergelot, P., Maugendre, D., Use of Chinese hamster ovary cell lines transfected with cloned human thyrotropin receptor for the measurement of thyroid-stimulating antibodies: advantages and difficulties 291, 67
- Masuda, M., Powell, M., Chen, S., Beer, C., Fichna, P., Rees Smith, B., Furmaniak, J., Autoantibodies to IA-2 in insulin-dependent diabetes mellitus. Measurements with a new immunoprecipitation assay 291, 53
- Maugendre, D., see Massart, C. 291, 67
- Meguro, K., see Kudo, S. 291, 83
- Merlini, P.A., see Ardissino, D. 291, 235
- Montecucco, C., see Rossetto, O. 291, 189
- Naccarato, R., see Herszényi, L. 291, 171
- Namera, A., Utsumi, Y., Yashiki, M., Ohtani, M., Imamura, T., Kojima, T., Direct colorimetric method for determination of organophosphates in human urine 291, 9
- Neff, L., see Delaissé, J.-M. 291, 223
- Nicolas, J.-P., see Lambert, D.A. 291, 19
- Ohtani, M., see Namera, A. 291, 9
- Pellizzari, R., see Rossetto, O. 291, 189
- Pendás, A.M., Uría, J.A., Jiménez, M.G., Balbín, M., Freije, J.P., López-Otín, C., An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies 291, 137
- Plebani, M., see Herszényi, L. 291, 171
- Powell, M., see Masuda, M. 291, 53
- Pownall, H., see Lambert, D.A. 291, 19
- Rees Smith, B., see Masuda, M. 291, 53
- Repetto, A., see Ardissino, D. 291, 235
- Réy, J.-M., see Rochefort, H. 291, 157
- Rizzo, C., Dionisi-Vici, C., D'Ippoliti, M., Fina, F., Sabetta, G., Federici, G., A simple and rapid HPLC method for simultaneous determination of plasma 7-dehydrocholesterol and vitamin E: its application in Smith-Lemli-Opitz patients 291, 97
- Rochefort, H., Garcia, M., Glondou, M., Laurent, V., Liaudet, E., Rey, J.-M., Roger, P., Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview 291, 157
- Roger, P., see Rochefort, H. 291, 157
- Rossetto, O., de Bernard, M., Pellizzari, R., Vitale, G., Caccin, P., Schiavo, G., Montecucco, C., Bacterial toxins with intracellular protease activity 291, 189
- Roveroni, G., see Herszényi, L. 291, 171
- Sabetta, G., see Rizzo, C. 291, 97
- Sasaki, T., see Kudo, S. 291, 83
- Schiavo, G., see Rossetto, O. 291, 189

- | | | | |
|-----------------------------------|----------|----------------------------------|----------|
| Sloane, B.F., see Koblinski, J.E. | 291, 113 | Vérité, F., see Massart, C. | 291, 67 |
| Smith, L.C., see Lambert, D.A. | 291, 19 | Vitale, G., see Rossetto, O. | 291, 189 |
| Sparrow, J.T., see Lambert, D.A. | 291, 19 | Vu, T.H., see Delaissé, J.-M. | 291, 223 |
| Šuškovič, S., see Cimerman, N. | 291, 89 | | |
| | | Watanabe, N., see Kudo, S. | 291, 83 |
| Takasawa, N., see Kudo, S. | 291, 83 | Werb, Z., see Delaissé, J.-M. | 291, 223 |
| Troen, T., see Delaissé, J.-M. | 291, 223 | Winding, B., see Delaissé, J.-M. | 291, 223 |
| Tulassay, Z., see Herszényi, L. | 291, 171 | | |
| | | Yashiki, M., see Namera, A. | 291, 9 |
| Ubbink, J.B., see Basso, L.E. | 291, 1 | | |
| Uría, J.A., see Pendás, A.M. | 291, 137 | | |
| Utsumi, Y., see Namera, A. | 291, 9 | | |



Subject index

Volume 291 (2000)

- Acute pancreatitis;** Trypsin; Chymotrypsin; Elastase; *p*-Aminobenzoic acid; Cholecystokinin; Chronic pancreatitis; Cancer **291, 201**
- AFP index;** Alpha-fetoprotein; Fetal; Albumin; Cerebrospinal fluid; Intrathecal synthesis **291, 35**
- Albumin;** Alpha-fetoprotein; Fetal; AFP index; Cerebrospinal fluid; Intrathecal synthesis **291, 35**
- Alpha-fetoprotein;** Fetal; Albumin; AFP index; Cerebrospinal fluid; Intrathecal synthesis **291, 35**
- p*-Aminobenzoic acid;** Trypsin; Chymotrypsin; Elastase; Cholecystokinin; Chronic pancreatitis; Acute pancreatitis; Cancer **291, 201**
- Analytical variation;** Erythrocyte; Plasma; Magnesium; Biological variation; Critical difference **291, 1**
- Apolipoproteins;** Lipoprotein lipase; Hyperlipoproteinemia; Protein cofactors **291, 19**
- Arthritis;** Matrix metalloproteinases; Invasion; Metastasis; Bone remodeling **291, 137**
- Autoantibodies;** Autoimmunity; Diabetes mellitus; Islet cell autoantibodies; IA-2 **291, 53**
- Autoimmunity;** Autoantibodies; Diabetes mellitus; Islet cell autoantibodies; IA-2 **291, 53**
- Biological variation;** Erythrocyte; Plasma; Magnesium; Analytical variation; Critical difference **291, 1**
- Bone remodeling;** Matrix metalloproteinases; Invasion; Metastasis; Arthritis **291, 137**
- Bone resorption;** Cathepsin K; Matrix metalloproteinase (MMP); Collagenase; MMP-9; Osteoclast; Osteoblast **291, 223**
- Breast cancer;** Metastasis; Proteases; Cathepsin D; Phagocytosis; Man-6-P/IGFII receptor; Cell proliferation; Prognostic marker **291, 157**
- Cancer;** Cathepsin B; Proteases; Tumor progression; Tumor invasion; Tumor-stromal interactions **291, 113**
- Cancer;** Cathepsin; Gastrointestinal tract; Plasminogen activator; Prognosis; Protease **291, 171**
- Cancer;** Trypsin; Chymotrypsin; Elastase; *p*-Aminobenzoic acid; Cholecystokinin; Chronic pancreatitis; Acute pancreatitis **291, 201**
- Carbimazole treatment;** TSAbs; Human thyrocytes; CHO transfected cells; JP26 cells; Graves' disease **291, 67**
- Cathepsin B;** Cancer; Proteases; Tumor progression; Tumor invasion; Tumor-stromal interactions **291, 113**
- Cathepsin D;** Metastasis; Breast cancer; Proteases; Phagocytosis; Man-6-P/IGFII receptor; Cell proliferation; Prognostic marker **291, 157**

- Cathepsin K**; Bone resorption; Matrix metalloproteinase (MMP); Collagenase; MMP-9; Osteoclast; Osteoblast **291**, 223
- Cathepsin**; Cancer; Gastrointestinal tract; Plasminogen activator; Prognosis; Protease **291**, 171
- Cell proliferation**; Metastasis; Breast cancer; Proteases; Cathepsin D; Phagocytosis; Man-6-P/IGFII receptor; Prognostic marker **291**, 157
- Cerebrospinal fluid**; Alpha-fetoprotein; Fetal; Albumin; AFP index; Intrathecal synthesis **291**, 35
- CHO transfected cells**; TSAb; Human thyrocytes; JP26 cells; Graves'disease; Carbimazole treatment **291**, 67
- Cholecystokinin**; Trypsin; Chymotrypsin; Elastase; *p*-Aminobenzoic acid; Chronic pancreatitis; Acute pancreatitis; Cancer **291**, 201
- Chronic pancreatitis**; Trypsin; Chymotrypsin; Elastase; *p*-Aminobenzoic acid; Cholecystokinin; Acute pancreatitis; Cancer **291**, 201
- Chymotrypsin**; Trypsin; Elastase; *p*-Aminobenzoic acid; Cholecystokinin; Chronic pancreatitis; Acute pancreatitis; Cancer **291**, 201
- Clostridial neurotoxins**; Metallo-proteases; Lethal factor of *Bacillus anthracis*; Vacuolating cytotoxin of *Helicobacter pylori* **291**, 189
- Collagenase**; Bone resorption; Cathepsin K; Matrix metalloproteinase (MMP); MMP-9; Osteoclast; Osteoblast **291**, 223
- Colorimetric test**; Organophosphates; Pesticides; Humans; Urine **291**, 9
- Coronary thrombosis**; Unstable angina; Myocardial infarction; Tissue factor **291**, 235
- Creatinine**; Human cystatin C; Cysteine proteinase inhibitory activity; Serum levels; 24-h variations **291**, 89
- Critical difference**; Erythrocyte; Plasma; Magnesium; Analytical variation; Biological variation **291**, 1
- Cysteine proteinase inhibitory activity**; Human cystatin C; Creatinine; Serum levels; 24-h variations **291**, 89
- 7-Dehydrocholesterol**; Vitamin E; Smith-Lemli-Opitz syndrome; HPLC **291**, 97
- Diabetes mellitus**; Autoimmunity; Autoantibodies; Islet cell autoantibodies; IA-2 **291**, 53
- Differential diagnosis**; HbF; Dyserythropoiesis **291**, 83
- Dyserythropoiesis**; HbF; Differential diagnosis **291**, 83
- Elastase**; Trypsin; Chymotrypsin; *p*-Aminobenzoic acid; Cholecystokinin; Chronic pancreatitis; Acute pancreatitis; Cancer **291**, 201
- Electrophoresis**; Haptoglobin; Hemoglobin; Gel permeation chromatography; Polymorphism; Reference values **291**, 43
- Erythrocyte**; Plasma; Magnesium; Analytical variation; Biological variation; Critical difference **291**, 1
- Fetal**; Alpha-fetoprotein; Albumin; AFP index; Cerebrospinal fluid; Intrathecal synthesis **291**, 35
- Gastrointestinal tract**; Cancer; Cathepsin; Plasminogen activator; Prognosis; Protease **291**, 171
- Gel permeation chromatography**; Electrophoresis; Haptoglobin; Hemoglobin; Polymorphism; Reference values **291**, 43
- Graves'disease**; TSAb; Human thyrocytes; CHO transfected cells; JP26 cells; Carbimazole treatment **291**, 67
- Haptoglobin**; Electrophoresis; Hemoglobin; Gel permeation chromatography; Polymorphism; Reference values **291**, 43
- HbF**; Dyserythropoiesis; Differential diagnosis **291**, 83
- Hemoglobin**; Electrophoresis; Haptoglobin; Gel permeation chromatography; Polymorphism; Reference values **291**, 43
- HPLC**; 7-Dehydrocholesterol; Vitamin E; Smith-Lemli-Opitz syndrome **291**, 97
- Human cystatin C**; Cysteine proteinase inhibitory activity; Creatinine; Serum levels; 24-h variations **291**, 89

- Human thyrocytes**; TSAb; CHO transfected cells; JP26 cells; Graves'disease; Carbimazole treatment 291, 67
- Humans**; Organophosphates; Pesticides; Urine; Colorimetric test 291, 9
- Hyperlipoproteinemia**; Apolipoproteins; Lipoprotein lipase; Protein cofactors 291, 19
- IA-2**; Autoimmunity; Autoantibodies; Diabetes mellitus; Islet cell autoantibodies 291, 53
- Intrathecal synthesis**; Alpha-fetoprotein; Fetal; Albumin; AFP index; Cerebrospinal fluid 291, 35
- Invasion**; Matrix metalloproteinases; Metastasis; Arthritis; Bone remodeling 291, 137
- Islet cell autoantibodies**; Autoimmunity; Autoantibodies; Diabetes mellitus; IA-2 291, 53
- JP26 cells**; TSAb; Human thyrocytes; CHO transfected cells; Graves'disease; Carbimazole treatment 291, 67
- Lethal factor of *Bacillus anthracis***; Metalloproteases; Clostridial neurotoxins; Vacuolating cytotoxin of *Helicobacter pylori* 291, 189
- Lipoprotein lipase**; Apolipoproteins; Hyperlipoproteinemia; Protein cofactors 291, 19
- Magnesium**; Erythrocyte; Plasma; Analytical variation; Biological variation; Critical difference 291, 1
- Man-6-P/IGFII receptor**; Metastasis; Breast cancer; Proteases; Cathepsin D; Phagocytosis; Cell proliferation; Prognostic marker 291, 157
- Matrix metalloproteinase (MMP)**; Bone resorption; Cathepsin K; Collagenase; MMP-9; Osteoclast; Osteoblast 291, 223
- Matrix metalloproteinases**; Invasion; Metastasis; Arthritis; Bone remodeling 291, 137
- Metalloproteases**; Clostridial neurotoxins; Lethal factor of *Bacillus anthracis*; Vacuolating cytotoxin of *Helicobacter pylori* 291, 189
- Metastasis**; Breast cancer; Proteases; Cathepsin D; Phagocytosis; Man-6-P/IGFII receptor; Cell proliferation; Prognostic marker 291, 157
- Metastasis**; Matrix metalloproteinases; Invasion; Arthritis; Bone remodeling 291, 137
- MMP-9**; Bone resorption; Cathepsin K; Matrix metalloproteinase (MMP); Collagenase; Osteoclast; Osteoblast 291, 223
- Myocardial infarction**; Coronary thrombosis; Unstable angina; Tissue factor 291, 235
- Organophosphates**; Pesticides; Humans; Urine; Colorimetric test 291, 9
- Osteoblast**; Bone resorption; Cathepsin K; Matrix metalloproteinase (MMP); Collagenase; MMP-9; Osteoclast 291, 223
- Osteoclast**; Bone resorption; Cathepsin K; Matrix metalloproteinase (MMP); Collagenase; MMP-9; Osteoblast 291, 223
- Pesticides**; Organophosphates; Humans; Urine; Colorimetric test 291, 9
- Phagocytosis**; Metastasis; Breast cancer; Proteases; Cathepsin D; Man-6-P/IGFII receptor; Cell proliferation; Prognostic marker 291, 157
- Plasma**; Erythrocyte; Magnesium; Analytical variation; Biological variation; Critical difference 291, 1
- Plasminogen activator**; Cancer; Cathepsin; Gastrointestinal tract; Prognosis; Protease 291, 171
- Polymorphism**; Electrophoresis; Haptoglobin; Hemoglobin; Gel permeation chromatography; Reference values 291, 43
- Prognosis**; Cancer; Cathepsin; Gastrointestinal tract; Plasminogen activator; Protease 291, 171
- Prognostic marker**; Metastasis; Breast cancer; Proteases; Cathepsin D; Phagocytosis; Man-6-P/IGFII receptor; Cell proliferation 291, 157
- Proteases**; Cathepsin B; Cancer; Tumor progression; Tumor invasion; Tumor-stromal interactions 291, 113
- Proteases**; Metastasis; Breast cancer; Cathepsin D; Phagocytosis; Man-6-P/IGFII receptor; Cell proliferation; Prognostic marker 291, 157
- Protease**; Cancer; Cathepsin; Gastrointestinal tract; Plasminogen activator; Prognosis 291, 171

- Protein cofactors;** Apolipoproteins; Lipoprotein lipase; Hyperlipoproteinemia **291, 19**
- Reference values;** Electrophoresis; Haptoglobin; Hemoglobin; Gel permeation chromatography; Polymorphism **291, 43**
- Serum levels;** Human cystatin C; Cysteine proteinase inhibitory activity; Creatinine; 24-h variations **291, 89**
- Smith-Lemli-Opitz syndrome;** 7-Dehydrocholesterol; Vitamin E; HPLC **291, 97**
- Tissue factor;** Coronary thrombosis; Unstable angina; Myocardial infarction **291, 235**
- Trypsin;** Chymotrypsin; Elastase; *p*-Aminobenzoic acid; Cholecystokinin; Chronic pancreatitis; Acute pancreatitis; Cancer **291, 201**
- TSAb;** Human thyrocytes; CHO transfected cells; JP26 cells; Graves'disease; Carbimazole treatment **291, 67**
- Tumor invasion;** Cathepsin B; Cancer; Proteases; Tumor progression; Tumor-stromal interactions **291, 113**
- Tumor progression;** Cathepsin B; Cancer; Proteases; Tumor invasion; Tumor-stromal interactions **291, 113**
- Tumor-stromal interactions;** Cathepsin B; Cancer; Proteases; Tumor progression; Tumor invasion **291, 113**
- Unstable angina;** Coronary thrombosis; Myocardial infarction; Tissue factor **291, 235**
- Urine;** Organophosphates; Pesticides; Humans; Colorimetric test **291, 9**
- Vacuolating cytotoxin of *Helicobacter pylori*;** Metallo-proteases; Clostridial neurotoxins; Lethal factor of *Bacillus anthracis* **291, 189**
- 24-h variations;** Human cystatin C; Cysteine proteinase inhibitory activity; Creatinine; Serum levels **291, 89**
- Vitamin E;** 7-Dehydrocholesterol; Smith-Lemli-Opitz syndrome; HPLC **291, 97**